Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Future CAGR is Anticipated for the Venous Thromboembolism Market Over the 2025–2034 Period?

In recent times, the size of the venous thromboembolism market has seen consistent expansion. It is projected to escalate from $2.44 billion in 2024 to $2.55 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 4.4%. The growth observed in the historical period can be associated with factors such as an aging population, advancements in anticoagulants, changes in reimbursement policies, and increased investments.

In the coming years, the market size of venous thromboprophylism is projected to grow steadily. The estimated value by 2029 will be around $3.02 billion, with a compound annual growth rate (CAGR) of 4.4%. A combination of factors such as improved global healthcare access, genetic risk evaluation, telemedicine, remote monitoring, patient education, and support are contributing to the growth during this forecast period. Significant trends observed during this period consist of extended thromboprophylaxis, the development of novel oral anticoagulants, personalized treatment strategies, and advancements in diagnostic imaging.

Which Primary Drivers Are Supporting the Continued Expansion of the Venous Thromboembolism Market?

The venous thromboembolism market is expected to flourish with the growth of the healthcare infrastructure. Products and services aimed at treating, curing, preventing, and providing necessary care for patients fall under the healthcare industry. The industry’s growth aids the improvement of necessary policies, educational programs, and institutional frameworks needed to implement VTE prevention protocols. As reported by the American Health Care Association in May 2023, there was an increase in the number of hospitals in the US to 6,129 from 6,093 in the previous year. Also, in the same month, the Office for National Statistics reported that the UK’s healthcare expenditure was around £292 billion in 2023, indicating a nominal rise of 5.6%. The long-term health and social care expenditure also saw a real-terms increase of 2.8%. These statistics establish that the growth of the healthcare industry significantly contributes to the venous thromboembolism market’s expansion. Additionally, another significant factor propelling the growth of the venous thromboembolism market is the rise in orthopedic procedures. These procedures play a pivotal role in treating spine and joint-related disorders and correcting skeletal abnormalities. Procedures like total knee arthroplasty (TKA), total hip arthroplasty (THA), or hip fracture surgery (HFS), known for their heightened risk of VTE, have led to an increased reliance on compression devices to prevent DVT. These devices are crucial in stoping the formation of blood clots in one’s deep leg veins, a major cause of venous thromboembolism (VTE). The National Library of Medicine reported in February 2023 that the number of THA and TKA procedures are expected to surge to 719,364 and 1,222,988, respectively, by 2040. Furthermore, by 2060, it is anticipated that TKAs and THAs will amount to 2,917,959 and 1,982,099 respectively. This surge in orthopedic procedures thus significantly propels the venous thromboembolism market’s growth.

Explore Comprehensive Insights Into The Global Venous Thromboembolism Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13001&type=smp

What Are the Major Players Making an Impact in the Venous Thromboembolism Market’s Growth?

Major companies operating in the venous thromboembolism market are:

• Pfizer Inc._x000D_

• Johnson and Johnson Limited_x000D_

• Merck and Co. Inc._x000D_

• AbbVie Inc._x000D_

• Bayer AG_x000D_

What Key Market Trends Are Shaping the Future of the Venous Thromboembolism Industry?

In a bid to bolster their standing in the venous thromboembolism market, major companies are innovating new anticoagulant medications and therapies. Such progress in anticoagulation can potentially yield more effective treatments for preventing or mitigating venous thromboembolism. Illustratively, Anthos Therapeutics, an American company that specializes in clinical-stage biotherapeutic products, secured regulatory clearance from the U.S Food and Drug Administration for their abelacimab anticoagulant drug in September 2022. This new drug, a fully human monoclonal antibody, was approved for reducing the risk of stroke and systemic embolism in individuals with atrial fibrillation. The recent innovation of the dual-action antibody abelacimab, administered monthly, is designed to enable hemostasis-sparing anticoagulation through the inhibition of Factor XI.

Secure Your Global Venous Thromboembolism Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report

What Are the Core Categories and Segments in the Venous Thromboembolism Market Driving Demand and Growth?

The venous thromboembolism market covered in this report is segmented –

1) By Type: Deep Vein Thrombosis, Pulmonary Embolism, Other Types

2) By Treatment: Anti-Clotting Medications,  Mechanical Devices, Thrombolytic Therapy, Other Treatment

3) By End Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By Deep Vein Thrombosis (DVT): Proximal DVT, Distal DVT, Asymptomatic DVT

2) By Pulmonary Embolism (PE): Acute PE, Chronic PE, Submassive PE

3) By Other Types: Thrombophlebitis, Superficial Vein Thrombosis, Post-Thrombotic Syndrome

What Regions Are Steering Growth in the Venous Thromboembolism Sector?

North America was the largest region in the venous thromboembolism market in 2024. The regions covered in venous thromboembolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

How Is the Definition of the Venous Thromboembolism Market Impacting Future Growth?

Venous thromboembolism (VTE) refers to a medical condition characterized by the formation of blood clots within the veins, which can lead to potentially serious or life-threatening complications. common symptoms of VTE include leg pain and swelling, rapid breathing, chest pain and more. The various treatment methods, such as anticoagulant medications, devices and thrombolytic therapy, are used for the treatment of VTE.

Browse Through More Similar Reports By The Business Research Company:

Blood And Blood Components Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-and-blood-components-global-market-report

Blood Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Patient Blood Management Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: